Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention (Augustus)

Next Previous
Trial Profile

An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention (Augustus)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Aspirin; Clopidogrel; Prasugrel; Ticagrelor; Vitamin K antagonists; Warfarin
  • Indications Acute coronary syndromes; Cardiovascular disorders; Myocardial infarction; Stroke; Thrombosis
  • Focus Adverse reactions
  • Acronyms AUGUSTUS
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 08 Apr 2024 Results (n=4438) assessing the safety of apixaban vs vitamin K antagonists (VKA) and aspirin vs. placebo in patients with AF presented at the 73rd Annual Scientific Session of the American College of Cardiology
  • 07 Nov 2022 Results(n=2290) assessing Reduced versus Standard Dose Apixaban in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention presented at the American Heart Association Scientific Sessions 2022
  • 07 Nov 2022 Results (n=4420 ) assessing whether benefits of Apixaban Over Warfarin are preserved independent of Warfarin time in therapeutic range, presented at the American Heart Association Scientific Sessions 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top